Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study

Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study
Trkulja et al., European Journal of Clinical Pharmacology, doi:10.1007/s00228-023-03479-3 (preprint 11/7/2022)
https://c19early.org/trkulja2.html